Healthcare
Live Price
Offline$22.52
+0.00% today
1Y Change
+8.79%
Window
Jun 25, 2025 → Jun 17, 2026
Coverage: 246 bars · Jun 25, 2025 → Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Fisher & Paykel Healthcare Corporation Limited (FSPKF) is a Healthcare stock with a market cap of $21.00B and listed on OTC. The stock last traded around $22.52 and up 8.8% across the available one-year price window (Jun 25, 2025 → Jun 17, 2026). Baseline metrics include revenue growth of -27.2%, EPS growth of +178.3%, a dividend yield of 1.2%. What stands out right now is revenue -27.2%, EPS +178.3%, free cash flow +391.8% with operating margin 27.2% and ROIC 19.0%. The dividend is present but secondary, with a yield around 1.2%. Valuation already assumes a fairly strong business story at P/E 49.9 and price/sales 10.0. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines FSPKF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
FSPKF
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
FSPKF Max Drawdown
-17.80%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for FSPKF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$1.9B
+18.6% YoY
FY Net Income
$524.2M
+39.1% YoY
Free Cash Flow
$440.6M
+185.2% YoY
Revenue Growth
-27.2%
EPS Growth
+178.3%
Gross Margin
63.6%
Net Margin
20.1%
Income statement
NZD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 1.3B | 1.8B | 1.6B | 1.6B | 1.9B |
| Gross Profit | 530M | 1.1B | 946M | 1.0B | 1.2B |
| Operating Income | -371M | 254M | 335M | 509M | 723M |
| EBITDA | 654M | 368M | 434M | 605M | 808M |
| Net Income | 377M | 133M | 250M | 377M | 524M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
NZD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 265M | 82M | 121M | 90M | 97M |
| Total Assets | 2.6B | 2.3B | 2.2B | 2.1B | 2.1B |
| Total Liabilities | 660M | 523M | 451M | 427M | 554M |
| Shareholder Equity | 1.9B | 1.8B | 1.8B | 1.7B | 1.5B |
| Total Debt | 153M | 189M | 146M | 104M | 118M |
| Net Debt | -111M | 107M | 25M | 14M | 21M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
625M
+92.8% YoY
Capital Expenditures
185M
-8.8% YoY
Free Cash Flow
441M
+185.2% YoY
Key ratios
Gross Margin
63.6%
Operating Margin
27.2%
Net Margin
20.1%
ROE
22.5%
Debt / Equity
0.07x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.